Prestige BioPharma, Largest Shareholder of Prestige Biologics, Increases Shareholdings by 103,600 Shares... Total Ownership Rate 60.37%

Prestige Biologics (334970), a specialized pharmaceutical CDMO company, disclosed its shareholding changes on July 10. Prestige BioPharma, the company's largest shareholder, increased its shareholding by 103,600 shares. According to the report, Prestige BioPharma and five related parties hold a total of 46,936,099 shares (60.37%). Key holdings include Prestige BioPharma with 31,122,728 shares (40.03%), Park So-yeon with 7,807,821 shares (10.04%), and Kim Jin-woo with 7,815,201 shares (10.05%). Kim Jin-woo's holdings rose by 103,600 shares (0.14 percentage points) due to a July 7 intra-day purchase of 771,1601 shares. The source of funds was stated as self-funded, totaling KRW 19,436,304,600. Prestige Biologics, listed on KOSDAQ since June 2, 2015, closed at KRW 1,780 on July 10, down 50 points (-2.73%) from the previous day.